Arrowhead Pharmaceuticals Secures TGA Approval for REDEMPLO® (plozasiran) in Australia, Broadening Access for Patients with Familial Chylomicronemia Syndrome (FCS) Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has announced a significant regulatory milestone with the approval of REDEMPLO by Australia’s Therapeutic Goods Administration…
Summit Therapeutics Announces Q1 2026 Financial Results and Highlights Key Operational Achievements Summit Therapeutics Inc. (NASDAQ: SMMT) has reported its financial results for the first quarter ended March 31, 2026, while also providing a comprehensive update on its clinical pipeline…
TRexBio Initiates Phase 1b Study of TRB-061 in Moderate-to-Severe Atopic Dermatitis with First Patient Dosed TRex Bio, Inc. (“TRexBio”), a clinical-stage biotechnology company focused on discovering and developing immunoregulatory therapies rooted in tissue regulatory T cell (Treg) biology, has announced…
U.S. FDA Accepts Priority Review for Gilead’s Once-Daily HIV Therapy Combining Bictegravir and Lenacapavir Gilead Sciences has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for an investigational once-daily, single-tablet regimen combining…
Strand Therapeutics Names Kunal Bhatia as Chief Financial Officer Strand Therapeutics, a clinical-stage biotechnology company focused on advancing programmable mRNA medicines, has announced the appointment of Kunal Bhatia as its new Chief Financial Officer. The move comes at a pivotal…
Samsung Bioepis and ATLATL Enter MoU to Advance Early-Stage Biotech Innovation Across Asia-Pacific Samsung Bioepis Co., Ltd. has entered into a strategic collaboration with ATLATL Innovation Center to strengthen early-stage biotechnology innovation across the Asia-Pacific region. The two organizations announced…
GSK Reports U.S. Food and Drug Administration Grants Breakthrough Therapy Designation and Priority Review Acceptance for Bepirovirsen in Chronic Hepatitis B as Potential First-in-Class Treatment Ionis Pharmaceuticals and its partner GSK have reached a significant regulatory milestone in the development…
AIDS Healthcare Foundation Files Shareholder Proposal Urging Gilead Sciences to Increase Transparency on Patent Exclusivity Practices Access to life-saving medicines remains one of the most critical challenges in global healthcare, and for many advocates, the issue extends far beyond scientific…
Mirai Bio to Debut Two Next-Generation Programs for Extrahepatic Targeted Nucleic Acid Delivery at the ASGCT 2026 Annual Meeting Mirai Bio, a company focused on enabling the next generation of nucleic acid therapeutics through advanced delivery technologies, has announced its…
Encoded Therapeutics to Present ETX101 Clinical Data in Dravet Syndrome at the 2026 ASGCT Presidential Symposium Encoded Therapeutics Inc. has announced its participation in the American Society of Gene & Cell Therapy 2026 Annual Meeting, where it will present new…
Mundipharma Reports Positive Phase III ReSPECT Topline Results for ▼REZZAYO (rezafungin) in Preventing Invasive Fungal Diseases in Allogeneic Stem Cell Transplant Patients Mundipharma has announced encouraging topline results from its pivotal Phase III ReSPECT clinical trial, highlighting the potential of…
Taiho Oncology, Taiho Pharmaceutical, and Araris Biotech Advance ADC Candidate ARC-02 into Phase 1 Clinical Trials Taiho Oncology, Inc., together with Taiho Pharmaceutical Co., Ltd. and Araris Biotech AG, has announced a key regulatory milestone in the development of its…